{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T01:56:20Z","timestamp":1788400580314,"version":"build-2803163510"},"reference-count":90,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Res Protoc"],"abstract":"\n Background<\/jats:title>\n Major depressive disorder (MDD) is common worldwide and can be highly disabling. People with MDD face many barriers to treatment and may not experience full symptom relief even when treated. Therefore, new treatment modalities are needed for MDD. Digital therapeutics (DTx) may provide people with MDD an additional treatment option.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n This study aimed to describe a phase 3 remote, multicenter, randomized, masked, sham-controlled trial evaluating the efficacy of a smartphone app\u2013based DTx (CT-152) in adult participants diagnosed with MDD, used as an adjunct to antidepressant therapy (ADT).<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Participants aged 22-64 years with a current primary diagnosis of MDD and an inadequate response to ADT were included. Participants were randomized 1:1 to CT-152 or a sham DTx. CT-152 is a smartphone app\u2013based DTx that delivers a cognitive-emotional and behavioral therapeutic intervention. The core components of CT-152 are the Emotional Faces Memory Task exercises, brief lessons to learn and apply key therapeutic skills, and SMS text messaging to reinforce lessons and encourage engagement with the app. The sham DTx is a digital working memory exercise with emotionally neutral stimuli designed to match CT-152 for time and attention. Participants took part in the trial for up to 13 weeks. The trial included a screening period of up to 3 weeks, a treatment period of 6 weeks, and an extension period of 4 weeks to assess the durability of the effect. Sites and participants had the option of an in-person or remote screening visit; the remaining trial visits were remote. Efficacy was evaluated using the Montgomery-\u00c5sberg Depression Rating Scale, the Generalized Anxiety Disorder-7, Clinical Global Impression\u2013Severity scale, the Patient Health Questionnaire-9, and the World Health Organization Disability Assessment Schedule 2.0. The durability of the effect was evaluated with the Montgomery-\u00c5sberg Depression Rating Scale and Generalized Anxiety Disorder-7 scale. Adverse events were also assessed. Satisfaction, measured by the Participant and Healthcare Professional Satisfaction Scales, and health status, measured by the EQ-5D-5L, were summarized using descriptive statistics.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n This study was initiated in February 2021 and had a primary completion date in October 2022.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n This represents the methodological design for the first evaluation of CT-152 as an adjunct to ADT. This study protocol is methodologically robust and incorporates many aspects of conventional pivotal pharmaceutical phase 3 trial design, such as randomization and safety end points. Novel considerations included the use of a sham comparator, masking considerations for visible app content, and outcome measures relevant to DTx. The rigor of this methodology will provide a more comprehensive understanding of the effectiveness of CT-152.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n ClinicalTrials.gov NCT04770285; https:\/\/clinicaltrials.gov\/study\/NCT04770285<\/jats:p>\n <\/jats:sec>\n \n International Registered Report Identifier (IRRID)<\/jats:title>\n RR1-10.2196\/56960<\/jats:p>\n <\/jats:sec>","DOI":"10.2196\/56960","type":"journal-article","created":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T16:12:40Z","timestamp":1718640760000},"page":"e56960","source":"Crossref","is-referenced-by-count":11,"title":["Evaluating the Efficacy of a Digital Therapeutic (CT-152) as an Adjunct to Antidepressant Treatment in Adults With Major Depressive Disorder: Protocol for the MIRAI Remote Study"],"prefix":"10.2196","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5780-2559","authenticated-orcid":false,"given":"Brian","family":"Rothman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7309-0914","authenticated-orcid":false,"given":"Mary","family":"Slomkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4260-7172","authenticated-orcid":false,"given":"Austin","family":"Speier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2004-2382","authenticated-orcid":false,"given":"A John","family":"Rush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2983-1110","authenticated-orcid":false,"given":"Madhukar H","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5285-466X","authenticated-orcid":false,"given":"Erica","family":"Lawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3294-8586","authenticated-orcid":false,"given":"Michael","family":"Fahmy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1782-4432","authenticated-orcid":false,"given":"Daniel","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4264-7248","authenticated-orcid":false,"given":"Dalei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1301-7752","authenticated-orcid":false,"given":"Ainslie","family":"Forbes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2024,8,20]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(21)00395-3"},{"key":"ref2","unstructured":"DepressionWorld Health Organization20212021-12-11https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/depression"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-021-01019-4"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32279-7"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2019.08.002"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-020-02758-y"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291718002301"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.15r01926"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1176\/appi.focus.20190028"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2018.01.004"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s10826-016-0603-6"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1080\/09638237.2019.1644494"},{"key":"ref13","unstructured":"Substance Abuse and Mental Health Services AdministrationKey substance use and mental health indicators in the United States: results from the 2022 National Survey on Drug Use and Health (HHS Publication No. PEP23-07-01-006, NSDUH Series H-58)2024-07-11https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/reports\/rpt42731\/2022-nsduh-nnr.pdf"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2021.09.038"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2006.163.11.1905"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/acps.13335"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1177\/070674371305800702"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2016.01.036"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291716002774"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2017.17030314"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/da.22640"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.7812\/TPP\/17-024"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.mhp.2019.200177"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S157475"},{"key":"ref25","unstructured":"Digital therapeutics: combining technology and evidence-based medicine to transform personalized patient careDigital Therapeutics Alliance20182022-08-04https:\/\/www.dtxalliance.org\/wp-content\/uploads\/2018\/09\/DTA-Report_DTx-Industry-Foundations.pdf"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.2196\/17662"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.4103\/jfmpc.jfmpc_105_20"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.5093\/clysa2021a2"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.2196\/19945"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-018-0247-x"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/bjc.12286"},{"key":"ref32","unstructured":"General wellness: policy for low risk devices guidance for industry and Food and Drug Administration staffUnited States Food and Drug Administration20192022-08-10https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/general-wellness-policy-low-risk-devices"},{"key":"ref33","unstructured":"Policy for device software functions and mobile medical applications: guidance for industry and Food and Drug Administration staffUnited States Food and Drug Administration20192022-08-10https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/policy-device-software-functions-and-mobile-medical-applications"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852923002225"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1002\/da.22266"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-018-0025-5"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2014.09.415"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.nlm.2011.06.006"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1037\/0033-2909.134.2.163"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1177\/2470547019877880"},{"key":"ref41","unstructured":"Patient-focused drug development: incorporating clinical outcome assessments into endpoints for regulatory decision-making guidance for industry, Food and Drug Administration staff, and other stakeholders (draft guidance)United States Food and Drug Administration20232023-06-09https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-incorporating-clinical-outcome-assessments-endpoints-regulatory"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0327(03)00198-8"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2020.11.066"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.3389\/fdgth.2022.823977"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20993"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.2196\/29154"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20227"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.2196\/33307"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20883"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.2174\/2666958702101010032"},{"key":"ref51","unstructured":"Developing novel endpoints generated by digital health technology for use in clinical trialsClinical Trial Transformation Initiative20222023-01-05https:\/\/ctti-clinicaltrials.org\/wp-content\/uploads\/2022\/03\/CTTI-Digital-Health-Trials-Novel-Endpoint-Acceptance-Recommendations.pdf"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2016.06.008"},{"key":"ref53","unstructured":"WeirKThe ascent of digital therapies20182022-09-13https:\/\/www.apa.org\/monitor\/2018\/11\/cover-digital-therapies"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-5949.2009.00102.x"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.11ac07225"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.747139"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1002\/mpr.1388"},{"issue":"7","key":"ref58","first-page":"28","volume":"4","author":"Busner, J","year":"2007","journal-title":"Psychiatry (Edgmont)"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.10.1092"},{"key":"ref60","unstructured":"Measuring health and disability: manual for WHO disability assessment schedule (?WHODAS 2.0)World Health Organization20102023-03-21https:\/\/www.who.int\/publications\/i\/item\/measuring-health-and-disability-manual-for-who-disability-assessment-schedule-(-whodas-2.0)"},{"key":"ref61","unstructured":"EQ-5D-5L user guide (version 3.0)EuroQol Research Foundation20192023-03-21https:\/\/euroqol.org\/wp-content\/uploads\/2023\/03\/EQ-5D-5LUserguide-08-0421.pdf"},{"key":"ref62","unstructured":"The columbia protocol (C0SSRS): about the protocolThe Columbia Lighthouse Project20162023-03-21https:\/\/cssrs.columbia.edu\/the-columbia-scale-c-ssrs\/about-the-scale\/"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.12793\/tcp.2019.27.1.6"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1016\/S2589-7500(20)30017-0"},{"key":"ref65","unstructured":"Guidance for the content of premarket submissions for software contained in medical devicesUnited States Food and Drug Administration20052023-04-17https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/content-premarket-submissions-device-software-functions"},{"key":"ref66","unstructured":"21 Code of Federal Regulations part 812United States Food and Drug Administration20232023-04-17https:\/\/www.ecfr.gov\/current\/title-21\/chapter-I\/subchapter-H"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1080\/10543400802609797"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.3389\/fdsfr.2022.900946"},{"key":"ref69","unstructured":"Software treatments for actively reducing severity of cognitive deficits in MDD (STARS-MDD)ClinicalTrials.gov20182022-09-14https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03310281"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2018.11.001"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2021.106320"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-016-1336-y"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2018.00274"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-021-05218-4"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-018-1639-5"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2014.13081055"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1037\/a0037496"},{"key":"ref78","unstructured":"Investigation of the freespira breathing system in the treatment of post traumatic stress disorder (PTSD)ClinicalTrials.gov20202022-08-16https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03039231"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(15)00536-2"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.2196\/43727"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2017.04.046"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20472"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pdig.0000002"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20673"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1016\/j.brat.2012.04.006"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.2196\/15001"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.1177\/20552076221104672"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1089\/tmj.2019.0065"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.2196\/20283"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-020-0224-8"}],"container-title":["JMIR Research Protocols"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.researchprotocols.org\/2024\/1\/e56960","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T17:46:41Z","timestamp":1782841601000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchprotocols.org\/2024\/1\/e56960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,20]]},"references-count":90,"URL":"https:\/\/doi.org\/10.2196\/56960","relation":{"has-preprint":[{"id-type":"doi","id":"10.2196\/preprints.56960","asserted-by":"object"}]},"ISSN":["1929-0748"],"issn-type":[{"value":"1929-0748","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,20]]}}}